scCM increased CD34+-EC proliferation, tubulogenesis, and migration compared to the control (scEBM). 5; (l) VE-cadherin; (m) occludin; (n) ZO-1; (o) tricellulin; (p) claudin 3. For images ACD, membranes were firstly probed with phospho-antibodies and then reprobed with pan-antibodies. 13287_2021_2608_MOESM3_ESM.tiff (1.6M) GUID:?E77841D8-F59A-4A72-AE7C-4196A92E2AC1 Additional file 4: Figure S4. Images used for western blotting analysis of ERK1/2, AKT, and VEGFR2 phosphorylation in proliferative CD34+-EC in response to acute administration (0C60 min) of scCM (5 g/mL) (Fig. ?(Fig.3a).3a). bFGF (basic FGF) represented in (a) was not considered for analysis. 13287_2021_2608_MOESM4_ESM.tiff (1.4M) GUID:?D7D8FF01-4C39-429E-808D-0AD015F5839B Additional file 5: Figure S5. Images used for western blotting analysis of ERK1/2, AKT, and VEGFR2 phosphorylation in proliferative CD34+-EC in response to administration (4 or 24 h) of scCM (5 g/mL) (Figure ?(Figure33b). 13287_2021_2608_MOESM5_ESM.tiff (1.5M) GUID:?4BC5237E-FA9E-4C3C-A208-CD0734E37AFC Additional file 6: Figure S6. Images used for western blotting analysis of ZO-1, VE-cadherin, occludin, claudin 5, claudin 3, non-phospho-catenin, and pan-catenin in CMECs in response to administration (48 h) of scCM (5 g/mL) (Fig. ?(Fig.4b4b and e). scCM-1: batch 1; scCM-2: batch 2. Analysis of scCM-2 were not presented in the manuscript. 13287_2021_2608_MOESM6_ESM.tiff (1.4M) GUID:?82C2E1B6-66E5-4938-AF0F-50F0F2FBAFC5 Additional file 7: Figure S7. Images used for western blotting analysis of ZO-1, VE-cadherin, occludin, and claudin 5 in BLECs in response to administration (48 h) of scCM (5 g/mL) (Fig. ?(Fig.4b).4b). scCM-1: batch 1; scCM-2: batch 2. Analysis of scCM-2 were not presented in the manuscript. 13287_2021_2608_MOESM7_ESM.tiff (1.0M) GUID:?F016A7EB-A15C-4CED-B7A2-380D37ECD751 Additional file 8: Figure S8. Images used for western blotting analysis claudin 5, tricellulin, VEGFR2, VCAM-1, COX-2, occludin, VE-Cadherin, ZO-1, and ERK1/2 in CMECs exposed to normoxic (N) Lenvatinib mesylate or OGD conditions and reoxygenation (R-N-scEBM; R-N-scCM; R-OGD-scEBM; R-OGD-scCM) (Fig. ?(Fig.55 and Additional file 17: Figure S15). 13287_2021_2608_MOESM8_ESM.tiff (1.9M) GUID:?E18CAA4D-E083-48E7-8F7C-2C09377DBDC0 Additional file 9: Figure S9. Images used for western blotting analysis of claudin 5, ZO-1, VE-cadherin, VEGFR2, VCAM, AKT, ERK1/2, and occludin in CMECs exposed to normoxic (N) or OGD conditions and reoxygenation (R-N-scEBM; R-N-scCM; R-OGD-scEBM; R-OGD-scCM) (Fig. ?(Fig.55 and Additional file 17: Figure S15). 13287_2021_2608_MOESM9_ESM.tiff (1.7M) GUID:?965FC8B6-0C49-446F-8F07-94E602E3F5C8 Additional file 10: Figure S10. Images used for western blotting analysis of VEGFR2, claudin 5, ZO-1, VE-cadherin, occludin, ICAM-1, AKT, ERK1/2, tricellulin, VCAM-1, and COX2 in BLECs exposed to normoxic (N) or OGD conditions and reoxygenation (R-N-scEBM; R-N-scCM; R-OGD-scEBM; R-OGD-scCM) (Fig. ?(Fig.66 and Additional file 17: Figure S15). 13287_2021_2608_MOESM10_ESM.tiff (2.0M) GUID:?A3998F3F-C20E-4C27-92FE-3AC5DEFCE57D Additional file 11: Figure S11. Images used for western blotting analysis of VEGFR2, MAIL occludin, VE-cadherin, ZO-1, claudin 5, ERK1/2, AKT, and ICAM-1 in BLECs exposed to normoxic (N) or OGD conditions and reoxygenation (R-N-scEBM; R-N-scCM; R-OGD-scEBM; R-OGD-scCM) (Fig. ?(Fig.66 and Additional file 17: Figure S15). 13287_2021_2608_MOESM11_ESM.tiff (1.7M) GUID:?A10B7EF8-4958-4E35-B591-8DF7B961CF07 Additional file 12: Figure S12. Images used for western blotting analysis of ABCA1, BCRP, and P-gp in CMECs (aCc) and BLECs (dCe) in response to administration (48 h) of scCM (5 g/mL) Lenvatinib mesylate (Additional Lenvatinib mesylate file 15: Figure S14d). scCM-1: batch 1; scCM-2: batch 2. Analysis of scCM-2 were not presented in the manuscript. 13287_2021_2608_MOESM12_ESM.tiff (1.5M) GUID:?2A390BE1-E6EC-4173-9990-5385A0B578AF Additional file 13: Figure S13. Images used for western blotting analysis of claudin 5, ZO-1, occludin, and Lenvatinib mesylate VE-cadherin in BLECs treated with vehicle or TNF (10 ng/mL) (Additional file?18: Figure S5c). 13287_2021_2608_MOESM13_ESM.tiff (1.7M) GUID:?64625498-D439-43D6-AC07-BD689A62BD2D Additional file 14: Table S1. 13287_2021_2608_MOESM14_ESM.xlsx (26K) GUID:?1BB84FF6-F2CA-47B0-8214-CCB6A81099CA Additional file 15: Figure S14. Effect of scCM treatment in the endothelial barrier properties. Co-staining with phalloidin and ZO-1 suggests that scCM promotes the accumulation of actin fibres at the cell borders (yellow arrowheads) and decreases its distribution across the cytoplasm of CMECs (a) and BLECs (b). scCM upregulates P-gp expression on BLECs, whereas it.